

Фітотерапія Часопис

Науково-практичне фахове видання

Голова редакційної ради

• Гарник Т. П., д-р мед. наук, проф. (м. Київ)

Редакційна рада

- Абрамов С. В., канд. мед. наук, доцент (м. Дніпро)
- Андришок Л. В., д-р мед. наук, проф. (м. Львів)
- Білай І. М., д-р медичних наук, проф. (м. Запоріжжя)
- Волошин О. І., д-р мед. наук, проф. (м. Чернівці)
- Глоба О. П., д-р мед. наук, доцент (м. Київ)
- Горюха Е. В., канд. мед. наук, доцент (м. Київ)
- Дарулі Н. П., канд. фарм. наук (м. Тернопіль)
- Добровольська Н. А., д-р псих. наук, доцент (м. Київ)
(заступник головного редактора)
- Колосова І. І., канд. біол. наук (м. Дніпро)
- Крайченко В. М., д-р біол. наук, проф. (м. Харків)
- Лоскутова І. В., д-р медичних наук, проф.
(м. Кропивницький)
- Mačiūskytė Sonata, д-р медицина, проф.
(м. Клайпеда, Литва)
- Остронська С. С., д-р біол. наук, проф. (м. Дніпро)
- Сендех Парчамі Газіє, канд. біол. наук (м. Київ-Іран)
- Радвин Я. Ф., д-р наук з держ. устр. канд. мед. наук,
проф. (м. Київ)
- Соколовський С. І., канд. мед. наук, доцент
(м. Дніпро)
- Хворост О. П., д-р фарм. наук (м. Харків)
- Шусть В. В., канд. мед. наук, доцент (м. Київ)
(відповідальний секретар)

Електронна сторінка журналу –
phytotherapy.vernadskyjournals.in.ua

Головний редактор

• Горчакова Н. О., д-р мед. наук, проф. (м. Київ)

Редакційна колегія

- Байбак В. М., д-р мед. наук, проф. (м. Дніпро)
(заступник головного редактора)
- Бєленічен І. Ф., д-р біол. наук, проф. (м. Запоріжжя)
(науковий редактор)
- Боднар О. І., д-р біол. наук, доцент (м. Тернопіль)
- Бурда Н. С., д-р фарм. наук, доцент (м. Харків)
(заступник наукового редактора)
- Весельський С. П., д-р біол. наук, с. н. с. (м. Київ)
- Віргінія Кукула-Кох, проф. (Польща)
- Галєн О. Ю., д-р біол. наук, проф. (м. Київ)
- Гараст Е., д-р фарм. наук, проф. (Азербайджан)
- Гладішев В. В., д-р фарм. наук, проф. (м. Запоріжжя)
- Григоренко Л. В., д-р мед. наук, доцент (м. Дніпро)
- Дроздова А. О., д-р фарм. наук, проф. (м. Київ)
- Дука Жанна, д-р наук, проф. (Мексика)
- Кончак О. О., д-р мед. наук, старший дослідник (м. Київ)
- Костіцiola Вінченцо, (Vincenzo Costigliola),
д-р медицини (Бельгія)
- Кузнецова В. Ю., д-р фарм. наук, доцент (м. Харків)
- Кучменко О. Б., д-р біол. наук, проф.
(м. Ніжин, Чернігівська обл.)
- Кириченко А. Г., MD, PhD, проф. (м. Дніпро)
- Марчиншин С. М., д-р фарм. наук, проф. (м. Тернопіль)
- Мінарченко В. М., д-р біол. наук, проф. (м. Київ)
- Марушко Ю. В., д-р мед. наук, проф. (м. Київ)
- Moskevičienė Daiva, д-р медицина, проф. (м. Клайпеда, Литва)
- Нікемцовська І. В., д-р мед. наук, проф. (м. Київ)
- Попова Н. В., д-р фарм. наук, проф. (м. Харків)
- Пузиренко Андрій, MD, PhD (Висконсин, США)
- Рахунський Р. В., д-р мед. наук, проф. (м. Дніпро)
- Рибак В. А., д-р біол. наук, доцент (м. Харків)
- Тітов Г. І., MD, PhD, проф. (м. Дніпро)
(заступник головного редактора)
- Утіс Клетінекс, Dk.MBA (Латвія)
- Шаторна В. Ф., д-р біол. наук, проф. (м. Дніпро)
- Пумна Т. С., MD, PhD, проф. (м. Дніпро)



Виданням дім
«Г. Вернадський»
2023

© Таврійський національний університет імені В.І. Вернадського, 2023
© Дніпровський медичний інститут традиційної і нетрадиційної медицини, 2023
© Всеукраїнська громадська організація «Асоціація фахівців з народної і нетрадиційної медицини України», 2023

Phytotherapy Journal

Scientific-practical professional periodical

Head of the Editorial Council

• Harnyk T. P., DSc (Medicine), Prof. (Kyiv)

Editorial Council

- Abramov S. V., PhD (Medicine), Associate Professor (Dnipro)
- Andriuk L. V., DSc (Medicine), Prof. (Lviv)
- Bilal I. M., DSc (Medicine), Prof. (Zaporizhzhia)
- Voloshyn O. L., DSc (Medicine), Prof. (Chernivtsi)
- Hlobo O. P., DSc (Pedagogy), Associate Professor (Kyiv)
- Horova E. V., PhD (Medicine), Associate Professor (Kyiv)
- Darzuli N. P., PhD (Pharmacy) (Ternopil)
- Dobrovol'ska N. A., DSc (Psychology), Associate Professor (Kyiv) (*Deputy Editor*)
- Kolosova I. L., PhD (Biology) (Dnipro)
- Kravchenko V. M., DSc (Biology), Prof. (Kharkiv)
- Loskutova I. V., DSc (Medicine), Prof. (Kropyvnytskyi)
- Mačiulskytė Sonata, MUDr., Prof. (Klaipėda, Lithuania)
- Ostrovska S. S., DSc (Biology), Prof. (Dnipro)
- Sepideh Parchami Hazae, PhD (Biology) (Kyiv-Iran)
- Radysh Y. F., DSc (Public Administration), PhD (Medicine), Prof. (Kyiv)
- Sokolovskiy S. I., PhD (Medicine), Associate Professor (Dnipro)
- Khvorost O. P., DSc (Pharmacy) (Kharkiv)
- Shust V. V., PhD (Pedagogy), Associate Professor (Kyiv) (*executive secretary*)

Chief Editor

• Horchakova N. O., DSc (Medicine), Prof. (Kyiv)

Editorial Board

- Baibakov V. M., DSc (Medicine), Prof. (Dnipro) (*Deputy Chief Editor*)
- Bielenichev I. F., DSc (Biology), Prof. (Zaporizhzhia) (*Science Editor*)
- Bodnar O. L., DSc (Biology), Associate Professor (Ternopil)
- Burda N. Ye., DSc (Pharmacy), Associate Professor (Kharkiv) (*Deputy Science Editor*)
- Veselskiy S. P., DSc (Biology), Senior Research Associate (Kyiv)
- Virginia Kukula-Koch, Prof. (Poland)
- Halkin O. Yu., DSc (Biology), Prof. (Kyiv)
- Garayev E., DSc (Pharmacy), Prof. (Azerbaijan)
- Hladyshev V. V., DSc (Pharmacy), Prof. (Zaporizhzhia)
- Hryhorenko L. V., DSc (Medicine), Associate Professor (Dnipro)
- Drozdova A. O., DSc (Pharmacy), Prof. (Kyiv)
- Duda Zhanna, DSc, Prof. (Mexico)
- Kopchak O. O., DSc (Medicine), Senior Researcher (Kyiv)
- Vincenzo Costigliola, MUDr. (Belgium)
- Kuznetsova V. Yu., DSc (Pharmacy), Associate Professor (Kharkiv)
- Kuchmenko O. B., DSc (Biology), Prof. (Nizhyn, Chernihiv region)
- Kyrychenko A. H., MD, PD, Prof. (Dnipro)
- Marchyshyn S. M., DSc (Pharmacy), Prof. (Ternopil)
- Minarchenko V. M., DSc (Biology), Prof. (Kyiv)
- Maryshko Yu. V., DSc (Medicine), Prof. (Kyiv)
- Mockevičienė Daiva, MUDr., Prof. (Klaipėda, Lithuania)
- Nizhenkovska I. V., DSc (Medicine), Prof. (Kyiv)
- Popova N. V., DSc (Pharmacy), Prof. (Kharkiv)
- Puzynenko Andrii, MD, PhD (Wisconsin, USA)
- Razumnyi R. V., DSc (Medicine), Prof. (Dnipro)
- Rybak V. A., DSc (Biology), Associate Professor (Kharkiv)
- Titov H. I., MD, PhD, Prof. (Dnipro) (*Deputy Chief Editor*)
- Ugis Kleitnickas, Dr.MBA (Lithuania)
- Shatorna V. F., DSc (Biology), Prof. (Dnipro)
- Shumna T. Ye., MD, PD, Prof. (Dnipro)

Web-site of the journal –
phytotherapy.vernadskyjournals.in.ua



Publishing House
"Helvetica"
2023

© V.I. Vernadsky Taurida National University, 2023
© Dnipropetrovsk Medical Institute of Traditional and Non-traditional Medicine, 2023
© NGO "Ukrainian Association for Non-traditional Medicine", 2023

UDC 615.322.6157.014

Sepideh PARCHAMI GHAAZAE

Candidate of Biological Sciences, Assistant, Assistant of the Department of Pharmacology, Clinical Pharmacology, Pathological Physiology, Kyiv Medical University, Boryspilska str., 2, Kyiv, Ukraine, 02099 (Sep_par_71@ukr.net)
ORCID: 0000-0002-3829-3270

Tetyana HARNYK

Doctor of Medical Sciences, Professor, Professor of the Department of Physical Education, Sports and Human Health, Vernadsky Taurida National University, John Mc Cain str., 33, Kyiv, Ukraine, 01042 (phitotherapy.chasopys@gmail.com)
ORCID: 0000-0002-5280-0363

Ella GOROVA

Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Physical Education, Sports and Health, Vernadsky Taurida National University, John Mc Cain str., 33, Kyiv, Ukraine, 01042 (gorova.ella@tntu.edu.ua)
ORCID: 0000-0003-0259-5469

Petro SEREDA

Doctor of Medical Sciences, Professor, Head of the Department of Pharmacology, Clinical Pharmacology, Pathological Physiology, Kyiv Medical University, Boryspilska str., 2, Kyiv, Ukraine, 02099 (p.sereda@kmu.edu.ua)
ORCID: 0009-0005-6005-9615

Kateryna MARCHENKO-TOLSTA

Senior Lecturer, Senior Lecturer of the Department of Pharmacology, Clinical Pharmacology, Pathological Physiology, Kyiv Medical University, Boryspilska str., 2, Kyiv, Ukraine, 02099 (k.marchenko-tolsta@kmu.edu.ua)
ORCID: 0000-0001-7744-5874

Murtaza HAMEED

5th year Student of Medicine, Department of Pharmacology, Clinical Pharmacology, Pathological Physiology, Kyiv Medical University, Boryspilska str., 2, Kyiv, Ukraine, 02099 (m.hameed.st@kmu.edu.ua)
ORCID: 0000-0003-0570-1108

DOI 10.32782/2522-9680-2023-1-37

To cite this article: Parchami Ghazae S., Harnyk T., Gorova E., Sereda P., Marchenko-Tolsta K., Hameed M. (2023). Rol fitozasobiv u terapii revmatoidnoho artrytu (Ohliadova stattia) [Role of phytochemicals treatments in managing rheumatoid arthritis (review article)]. *Fitoterapiia. Chasopys – Phytotherapy. Journal*, 1, 37–43, doi: 10.32782/2522-9680-2023-1-37

**ROLE OF PHYTOCHEMICALS TREATMENTS IN MANAGING RHEUMATOID ARTHRITIS
(REVIEW ARTICLE)**

Non-steroidal anti-inflammatory drugs are one of the symptomatic treatment options for rheumatoid arthritis (RA). However, these medications are known to have multiple adverse effects. Although biological medications target molecular pathways involved in the inflammatory process of RA, there is a lack of long-term safety data. This review aims to present the novel insights of recent studies investigating medicinal plants, phytochemicals and their pharmacological activities against RA. Punicagin reduces release of LPS-induced nitric oxide, TNF- α , and IL-6 by suppressing NF- κ B and MAPK signaling pathways that are responsible for apoptosis of chondrocytes. Anthocyanins decrease the number of Th17 cells and suppress Th17 cells differentiation *in vivo* and *in vitro*. Also, anthocyanins inhibit osteoclasts via downregulation of cytokines including IL-1, IL-6, IL-17, and TNF- α *in vitro*. Oral ellagic acid in arthritic rats considerably decreases paw edema and levels of chitinase-3-like protein-1, which is induced via the NF- κ B pathway and overexpression of which is associated with the inflammatory process of RA in chondrocytes and synovial tissue. Punic acid reduces MMP9 gene expression, associated with the activation of NF- κ B, which may mediate its anti-inflammatory effect in osteoarthritis. Although to date natural products are mainly used as nutraceuticals, the treatment of RA by medicinal plants needs more investigation to fully explore their potential as pharmacological agents in the treatment of autoimmune inflammatory diseases.

Key words: rheumatoid arthritis, punicagin, anthocyanins, ellagic acid, punic acid, anti-inflammatory phytochemicals.

Сенідех ПАРЧАМІ ГАЗАЕ

кандидат біологічних наук, асистент, асистент кафедри фармакології, клінічної фармакології, патологічної фізіології, ПБНЗ «Київський медичний університет», вул. Бориспільська, 2, м. Київ, Україна, 02099 (Ser.par.71@ukr.net)

ORCID: 0000-0002-3829-3270

Тетяна ГАРНИК

доктор медичних наук, професор, професор загальноузівської кафедри фізичного виховання, спорту і здоров'я людини, Таврійський національний університет імені В.І. Вернадського, вул. Джона Маккейна, 33, м. Київ, Україна, 01042 (phitotherapy.chasopys@gmail.com)

ORCID: 0000-0002-5280-0363

Елла ГОРОВА

кандидат медичних наук, доцент, доцент загальноузівської кафедри фізичного виховання, спорту і здоров'я людини, Таврійський національний університет імені В.І. Вернадського, вул. Джона Маккейна, 33, м. Київ, Україна, 01042 (gorova.ella@tntu.edu.ua)

ORCID: 0000-0003-0259-5469

Петро СЕРЕДА

доктор медичних наук, професор, завідувач кафедри фармакології, клінічної фармакології, патологічної фізіології, ПБНЗ «Київський медичний університет», вул. Бориспільська, 2, м. Київ, Україна, 02099 (p.sereda@kmu.edu.ua)

ORCID: 0009-0005-6005-9615

Катерина МАРЧЕНКО-ТОЛСТА

старший викладач, старший викладач кафедри фармакології, клінічної фармакології, патологічної фізіології, ПБНЗ «Київський медичний університет», вул. Бориспільська, 2, м. Київ, Україна, 02099 (k.marchenko-tolsta@kmu.edu.ua)

ORCID: 0000-0001-7744-5874

Муртаза ХАМІД

студент 5-го курсу медичного факультету, ПБНЗ «Київський медичний університет», вул. Бориспільська, 2, м. Київ, Україна, 02099 (m.hameed.st@kmu.edu.ua)

ORCID: 0000-0003-0570-1108

DOI 10.32782/2522-9680-2023-1-37

Бібліографічний опис статті: Парчамі Газас С., Гарник Т., Горова Е., Середя П., Марченко-Толста К., Хамід М. (2023). Роль фітозасобів у терапії ревматоїдного артриту (оглядова стаття). *Фітотерапія. Часопис*, 1, 37–43, doi: 10.32782/2522-9680-2023-1-37

РОЛЬ ФІТОЗАСОБІВ У ТЕРАПІЇ РЕВМАТОЇДНОГО АРТРИТУ (ОГЛЯДОВА СТАТТЯ)

Нестероїдні протизапальні препарати є одним із варіантів симптоматичного лікування ревматоїдного артриту (РА). Однак відомо, що вони мають численні побічні ефекти. Незважаючи на те, що біологічні препарати спрямовані на молекулярні шляхи запалення, бракує даних про довгострокову безпеку щодо РА. Цей огляд має на меті представити нові ідеї остаточно досліджених лікарських рослин, фітохімічних речовин та їх фармакологічні ефекти щодо РА. Пупікалатин зменшує вивільнення LPS-індукованого оксиду азоту, TNF- α та IL-6 шляхом пригнічення сигнальних шляхів NF- κ B і MAPK, які відповідають за апоптоз хондроцитів. Антоціани зменшують кількість клітин Th17 і прискорюють диференціацію клітин Th17 *in vivo* та *in vitro*. Крім того, антоціани інгібують остеокластичні шляхи зниження регуляції цитокінів, включаючи IL-1, IL-6, IL-17 і TNF- α *in vitro*. Елагова кислота у щурі з артритом значно зменшує набряк лапи та рівні хітинати-3-подібного білка-1, який індукуюється через шлях NF- κ B і надмірна експресія якого пов'язана із запальним процесом у хондроцитах і синовіальній тканині. Пупікова кислота збільшує експресію гена MMP9, пов'язану з активацією NF- κ B, що може опосередковувати її протизапальну дію у разі остеоартриту. Хоча на сьогодні природні сполуки в основному використовуються як купірувальники, терапія РА лікарськими рослинами потребує додаткових досліджень, щоб повністю вичити їхній потенціал як фармакологічних засобів у лікуванні аутоімунних запальних захворювань.

Ключові слова: ревматоїдний артрит, пупікалатин, антоціани, елагова кислота, пупікова кислота, протизапальні фітохімічні речовини.

Introduction. Rheumatoid arthritis (RA) is a chronic systemic inflammatory and autoimmune disease that essentially affects the joints. Although the severity of RA has reduced during recent decades, the disease prevalence has risen. According to population-based studies, the global prevalence of RA between 1980 and 2019 was 460 per 100,000 population. Trend analysis showed that RA was observed more in developed countries than developing countries (Finckh et al., 2022, pp. 591–602; Almutairi, 2020, pp. 863–877). This disease arises more in adult populations and is characterized by swelling, redness, pain and stiffness and progressive disability, affecting multiple joints symmetrically (Kalonji, Chakraborty, & Biswas, 2020, pp. 179–190). The role of several auto antibodies such as rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein antibodies (anti-CarP) in the pathogenesis of RA is evident. In synovial joints, type 1 T helper cells (Th1) are involved in the activation of macrophages that induce the production of pro-inflammatory cytokine like tumor necrosis factor (TNF) (Mueller et al., 2021, p. 3017). Although recent research has shown that interleukin (IL)-24 possesses anti-inflammatory effects, it (together with IL-20) was detected to be enhanced in plasma from patients with RA (Zhong, Zhang, & Chong, 2022, p. 627). Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the symptomatic treatment options for RA. However, these medications are known to have multiple adverse effects including nephrotoxicity, gastrointestinal bleeding and ulceration, increasing blood pressure and the risk of first hospitalization due to congestive heart failure. In order to control these reactions it is recommended to administer NSAIDs for a short period of time and in the lowest effective dose (Wongrakpanich, Wongrakpanich, & Melhado, 2018, pp. 143–150). Conventional disease modifying anti-rheumatic drugs (DMARDs) are usually the first choice to diminish disability and improve long-term outcomes for people with RA. Biologics are much more costly than other subsets of DMARDs, they are commonly used as partial responders to traditional DMARDs. Although the combination of biologics and traditional DMARDs has demonstrated improved efficacy, the potential benefits and harms (such as cancer and infections) are still controversial (Singh et al., 2016, p. CD012183). Various treatment strategies aim to suppress the activity of the disease. The introduction of synthetic and biologic DMARDs in very early stages of RA minimizes joint damage and functional disability, optimizing outcomes for patients. However, in spite of applying aggressive pharmacologic treatment regimens early in disease onset, complete clinical remission is not

achieved (Guo et al., 2018, p. 15). Although biological medications seem to effectively target molecular pathways involved in the inflammatory process of RA, there is a lack of long-term safety data regarding their use. Moreover, biologic drugs appear to have some disadvantages. Among these is their chemical and physical volatility. Immunobiologics should be stored, distributed and transported at specific temperatures (2–8°C) in order to avoid compromising their safety and efficacy. Patients need to be informed about home storage temperature condition monitoring via instructions provided by drug manufacturers (de Assis Damasceno et al., 2020, pp. 1–6). Various investigations have demonstrated an increased prevalence in the use of herbal medicine in developing countries. Since ancient times, herbs have been utilized as medicines for treating numerous diseases including inflammatory diseases. Interestingly, a rise in the prevalence of herbs used as complementary and alternative medicine among chronic disease patients has been reported in recent years (Peltzer & Pengpid, 2019, pp. 573–582; Welz, Emberger-Klein, & Menrad, 2018, p. 92). The anti-inflammatory properties of some herbal products are well-known and they have fewer unwanted effects than existing anti-inflammatory medications. As such, herbs and their derivatives constitute a promising arena in novel medical therapies. Furthermore, the cost-effectiveness of natural products has been explored and summarized by high quality studies (Xiong et al., 2022, p. 765226).

This article aims to present a review of novel insights into the use of medicinal plants, phytochemicals and their pharmacological activities against RA that have already been investigated via recent *in vivo*, *in vitro* experiments and clinical trials.

Anti-inflammatory phytochemicals and their mechanism of actions. Inflammation is a pathological process characterized by the accumulation of pro-inflammatory mediators at the site of cell or tissue injury. Continuous inflammatory responses may lead to different types of autoimmune diseases such as RA. The pathological process in RA involves macrophages and lymphocytes migrating to the synovium of joints, causing synovitis. Certain phytochemicals are considered to inhibit the release of inflammatory molecules to suppress inflammatory responses (Shin et al., 2020, p. 5932; Gandhi et al., 2022, pp. 1–15).

Punicalagin. Is the precursor of ellagitannin and has been reported to be the most active polyphenol obtained from different parts of the pomegranate tree (*Punica granatum* Linn.). Methanolic (and ethanolic) pomegranate peels extract contains a high amount of bioactive compounds, including punicalagin

(10–50 mg/g) (Xu et al., 2021, pp. 1–12). Historically, seeds and juices are believed to have been taken as supplements to reduce the clinical symptoms of RA (Singh, Singh, & Mahajan, 2020, pp. 1306–1327). Marques and coauthors (2016) have already revealed that Punicalagin diminished TNF α and interleukin (IL) 6 secretion in macrophages and primary human chondrocytes with lipopolysaccharide (LPS)-induced inflamed RAW264.7. (Marques et al., 2016, pp. 463–467). Nuclear factor kappa B (NF- κ B) is a transcription factor that is activated by inducers such as cytokines in the cytoplasm of various types of immune cells. It migrates to the nucleus where it in turn induces transcription of target genes that mediate inflammatory responses, including those involving cytokines and chemokines. It is worth noting that many findings confirm activated NF- κ B can be detected in human and animal arthritis synovium. (Singh, Singh, & Mahajan, 2020, pp. 1306–1327).

Cao et al. (2019, p. 2794) demonstrated that in RAW264.7, in a mouse cultured macrophage cell line that was pre-treated with punicalagin and LPS, punicalagin reduced release of LPS-induced nitric oxide (NO), TNF- α , and IL-6 by suppressing NF- κ B and the mitogen-activated protein kinase (MAPK) signaling pathway that is responsible for apoptosis of chondrocytes. These results testify to the anti-inflammatory property of punicalagin via its ability to affect different inflammatory pathways.

Anthocyanins (ACNs). Are a subtype of flavonoids; water-soluble polyphenol compounds and which naturally exist in fruits and vegetables. Pelargonidin, delphinidin, cyanidin, peonidin, petunidin, and malvidin are widespread ACNs, present in many common plants. They have been shown to represent potent anti-inflammatory, anti-oxidant, anti-cancer, anti-obesity and immunomodulatory activity (Salehi et al., 2020, pp. 1–20). The role of oxidative stress as one of the factors in the pathogenesis of RA is well-known. The regulation of oxidative stress by ACNs has been demonstrated in recent studies (Li et al., 2019, pp. 6815–6828; Min et al., 2015, pp. 1–17). The dysregulation of T helper 17 (Th17) cells which secrete proinflammatory IL 17 plays an important role in inflammation of affected joints in RA and may contribute to the destruction of cartilage and bone (Miao, Zhao, & Chen, 2022, pp. 1–9; Min et al., 2015, pp. 1–17). Decreasing the number of Th17 cells and the suppression of Th17 cells differentiation via the effect of oral ACNs has been examined *in vivo* and *in vitro* by Min and coauthors (2015). Furthermore, the authors reported the inhibitory effect of ACNs on osteoclasts via the downregulation of cytokines including IL-1, IL-6, IL-17,

and TNF- α *in vitro*. Although these studies suggest ACN therapy could represent a useful, novel approach in moderating inflammatory processes involved in chronic inflammatory disease, the results indicate that the oral bioavailability of ACN is low and its conjugated metabolites are released through bile without systemic distribution. It is worth noting that, not only the chemical structure of ACNs, but factors such as gut microbiota and metabolic process may affect the bioavailability of these natural compounds. Recent data proposes that cyanidin-3-O-glucoside may possess a higher bioavailability than other ACNs (Salehi et al., 2020, pp. 1–20; Kozłowska, & Dzierżanowski, 2021, pp. 1–17).

Ellagic acid (EA). Is a widely-distributed naturally bioactive phenolic agent, found predominantly in berries and nut kernels in different concentrations. The bur of the plant *Castanea sativa* Mill (sweet chestnut), the mesocarp of *Punica granatum* L. (pomegranate) and the fresh weight base of *Rubus idaeus* L. (raspberry) all contain a high EA content. The pronounced biological properties of EA such as anti-inflammatory, anti-oxidant, anti-apoptotic and anti-mutagenic effects have been well-documented. Additionally, the antidiabetic, hepatoprotective, neuroprotective and cardioprotective capacity of EA has been summarized by Sharifi-Rad and coauthors (Sharifi-Rad et al., 2022, pp. 1–24). The effect of EA on various indices and possible mechanisms involved in the pathogenesis of RA has been investigated in Freund's complete adjuvant (FCA)-induced arthritis rats by Fikry and coauthors (2019). Administration of oral EA (50 mg/kg/day) for 20 days in the rats considerably decreased paw edema and levels of chitinase-3-like protein-1 (CHI3L1). CHI3L1 is an inflammatory marker induced via the NF- κ B pathway and its over expression by chondrocytes and synovial tissue is associated with the inflammatory process of RA. Moreover, the study showed EA reduced cartilage destruction, synovial hyperplasia and bone erosion generated by Freund's adjuvant. Significant suppression of caspase-3 expression in models treated with EA testifies to the anti-apoptotic property of this biologic compound (Fikry, Gad, & Eid, 2019, pp. 878–886).

A study carried out by Lin and colleagues (2020) assessing the protective effects of EA in osteoarthritis suggests that EA suppresses secretion of iNOs (inducible nitric oxide synthase) and COX-2 (cyclooxygenase) in cultured human articular chondrocytes with IL-1 β -induced inflammation. Moreover, they observed that EA could impede the destruction of cartilage surface and decrease Osteoarthritis Research Society International (OARSI) grades in osteoarthritic mice models *in vivo* (Lin et al., 2020, pp. 1–9). The results of the

trial conducted by Ghoochani, Karandish and Mowla (2016, pp. 4377–4381) on 38 patients revealed that the consumption of pomegranate juice, which is rich in EA, markedly diminished the stiffness score and improved cartilage destruction and physical function. Although it has been proposed as a therapy due to its potential benefits and little toxicity to normal cells, poor water-solubility and limited oral bioavailability restrict the efficacy of dietary EA. In this regard, a number of studies are being conducted, specifically focusing on drug delivery systems and formulation strategies to improve the bioavailability of EA. Micronized EA powder particles, amorphous EA dispersion, EA inclusion complexes (in cyclodextrins), EA encapsulated in arene-ruthenium metalla-prism cages, EA-polymers, and chitosan (CS) micro/nanospheres are some examples of such biopharmaceutical technologies aiming to allow for the administration of EA in a more bioavailable form (Zuccari et al., 2020, p. 3353).

Punicic acid (PA). Is known as a conjugated linoleic fatty acid and the main bioactive compound of pomegranate seed oil. Its anti-inflammatory, antioxidant, antidiabetic and anti-carcinogenic properties have been recently reported (Aruna, Venkataramanamma, & Singh, 2016, pp. 16–27). Taherian, Maghsoudi and Vaziri (2018, pp. 31–44) examined *in vitro* the effect of PA on LPS-induced matrix metalloproteinases (matrixins, MMPs) gene expression in synoviocytes. These play a major role in pathogenesis of osteoarthritis by degrading the cartilage's extracellular matrix (ECM). The study revealed that PA reduces MMP9 gene expression, the overexpression of which is associated with activation of nuclear factor- κ B (NF- κ B) (Li et al., 2012, pp. 2096–2106). This may mediate the anti-inflammatory effect of PA in osteoarthritis.

Future perspectives. Research interest in a combination of phytotherapy and conventional, Western medication is rising worldwide. Phytochemicals are being investigated *in vitro*, *in vivo* and to a lesser extent in human trials, for better understanding of their potential benefits as therapy for many diseases. Herbs have demonstrated any ability to influence metabolic and immune system functions. Plant materials have been reported to be useful in the treatment of mental disorders, inflammatory diseases and cancers (Mata, Figueroa, & Navarrete, 2019, pp. 1–142).

The established origin of many modern medications in ethnobotanical remedies testifies to the important role of phyto-compounds not only in traditional but conventional medicine. Increasingly, studies are investigating the role of herbal medicine in treating autoimmune disorders (e.g., multiple sclerosis, Crohn's disease, ulcerative colitis, atopic dermatitis, and RA). Preliminary results from many recent studies have shown the effect of immunomodulatory plants on the immune system as immunostimulants and/or immunosuppressors. However, regarding the immunomodulatory power of some bioactive compounds, the result of clinical studies differs from those in experimental models. Thus, the lack of reliable data in clinical studies is the main limitation for supporting experimental evidence. The incompatible anti-inflammatory or proinflammatory properties of these bioactive constituents in different autoimmune disorders further necessitates more supportive clinical trials (Di Sotto, Vitalone & Di Giacomo 2020, p. 468). Assessing the awareness of health care professionals on the safety of herbal medicine has gained growing interest worldwide. Accordingly, due to rising importance of natural products in the medical sphere, health care professionals require training to recognize the pharmacokinetic interactions of concomitant use of herbal medicines with conventional drugs, result of natural remedies overdose, tolerance, hypersensitivity, their impact on different organs, toxicity and teratogenicity (Hasen, & Hashim, 2021, pp. 2001–2008). The importance of health education programs to improve knowledge and awareness of health care providers regarding medicinal plants benefits and safety should be considered as research interest in this area continues to grow.

Conclusion. In recent years, growing evidence has highlighted the fact that biological agents possess the ability to block inflammatory mediators and modulate the immune system, marking them as candidate drugs for the treatment of chronic inflammatory diseases such as RA. However, planning for more clinical trials to investigate pharmacological potential of herbal medicine is necessary. Although to date natural products are mainly used as nutraceuticals, the treatment of RA by medicinal plants needs more investigation to fully explore their potential as pharmacological agents in the treatment of autoimmune inflammatory diseases.

REFERENCES

- Almutairi, K., Nossent, J., Preen, D. (2020). The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatology international*, 41(5), 863–877. DOI: 10.1007/s00296-020-04731-0.
- Aruna, P., Venkataramanamma, D., & Singh, A. (2016). Health Benefits of Punicic Acid: A Review. *Comprehensive Reviews in Food Science and Food Safety*, 15(1), 16–27. DOI: 10.1111/1541-4337.12171.
- Cao, Y., Chen, J., Ren, G., Zhang, Y., Tan, X., Yang, L. (2019). Punicic acid Prevents Inflammation in LPS- Induced RAW264.7 Macrophages by Inhibiting FoxO3a/Autophagy Signaling Pathway. *Nutrients*, 11(11),2794, 1–14 (14 pages). DOI: 10.3390/nu11112794.

- De Assis Damasceno, T.M., Fernandes, V., Silva C.A. L.D., Silva, A.M.C. D., Ishikawa Cezar Santos, L.C., da Silva e Lima, V.P. (2020). Storage Conditions of Immunobiologicals and their Influence on the Efficacy and Safety in the Treatment of Autoimmune Rheumatic Diseases. *The Open Rheumatology*, 14, 1–6 (6 pages). DOI: 10.2174/1874312902014010001.
- Di Sotto, A., Vitalone, A., & Di Giacomo, S. (2020). Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview. *Vaccines (Basel)*, 8(3), 1–34 (34 pages). DOI: 10.3390/vaccines8030468.
- Fikry, E.M., Gad, A.M., & Eid, A.H. (2019). Caffeic acid and ellagic acid ameliorate adjuvant-induced arthritis in rats viatargeting inflammatory signals, chitinase-3-like protein-1 and angiogenesis. *Biomedicine & Pharmacotherapy*, 110, 878–886. DOI: 10.1016/j.biopha.2018.12.041.
- Finckh, A., Gilbert, B., Hodgkinson, B., Bae, S.C., Thomas, R., Deane, K. D., ... Lauper, K. (2022). Global epidemiology of rheumatoid arthritis. *Nature Reviews Rheumatology*, 18(10), 591–602. DOI: 10.1038/s41584-022-00827-y.
- Gandhi, Y., Kumar R., Grewal, J., Rawat, H., Mishra, S.K., Kumar, V., ... Acharya, R. (2022). Advances in anti-inflammatory medicinal plants and phytochemicals in the management of arthritis: A comprehensive review. *Food Chemistry Advances*, 1(2022), 1–15 (15 pages). URL: <https://doi.org/10.1016/j.focha.2022.100085>.
- Ghoochani, N., Karandish, M., & Mowla, K. (2016). The effect of pomegranate juice on clinical signs, matrix metalloproteinases and antioxidant status in patients with knee osteoarthritis. *The Journal of the Science of Food and Agriculture*, 96(13), 4377–4381. DOI: 10.1002/jsfa.7647.
- Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N.J., Xu, J. (2018). Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. *Bone Research*, 6, 15, 1–14 (14 pages). Doi: 10.1038/s41413-018-0016-9.
- Hasen, G., & Hashim, R. (2021). Current Awareness of Health Professionals on the Safety of Herbal Medicine and Associated Factors in the South West of Ethiopia. *J. of multidisciplinary healthcare*, 14, 2001–2008. DOI: 10.2147/JMDH.S321765.
- Kaloni, D., Chakraborty, D., & Biswas, S. A review on the efficacy of phytochemicals for Rheumatoid arthritis. *Academia J. of Medicinal Plants*, 8(12), 179–190. DOI: 10.15413/ajmp.2020.0142.
- Kozłowska, A., & Dzierżanowski, T. (2021). Targeting Inflammation by Anthocyanins as the Novel Therapeutic Potential for Chronic Diseases: An Update. *Molecules*, 26(14), 4380, 1–17 (17 pages). DOI: 10.3390/molecules26144380.
- Li, K., Zhang, M., Chen, H., Peng, J., Jiang, F., Shi, X., ... Jia, Y. (2019). Anthocyanins from black peanut skin protect against UV-B induced keratinocyte cell and skin oxidative damage through activating Nrf2 signaling. *Food & Function*, 10(10), 6815–6828. DOI: 10.1039/c9fo00706g.
- Li, Y.F., Xu, X.B., Chen, X.H., Wei, G., He, B., Wang, J.D. (2012). The nuclear factor- κ B pathway is involved in matrix metalloproteinase-9 expression in RU486-induced endometrium breakdown in mice. *Human Reproduction*, 27(7), 2096–2106. DOI: 10.1093/hmrp/des110.
- Lin, Z., Lin, C., Fu, C., Lu, H., Jin, H., Chen, Q., Pan, J. (2020). The protective effect of Ellagic acid (EA) in osteoarthritis: An in vitro and in vivo study. *Biomedicine & Pharmacotherapy*, 125(2020), 109845, 1–9 (9 pages). DOI: 10.1016/j.biopha.2020.109845.
- Marques, L.C., Pinheiro, A.J., Araujo, J.G., de Oliveira, R.A., Silva, S.N., Abreu, I.C., ... Lima-Neto, L.G. (2016). Anti-Inflammatory Effects of a Pomegranate Leaf Extract in LPS-Induced Peritonitis. *Planta Medica*, 82(17), 1463–1467. DOI: 10.1055/s-0042-108856.
- Mata, R., Figueroa, M., & Navarrete, A. (2019). Chemistry and Biology of Selected Mexican Medicinal Plants. *Progress in the chemistry of organic natural products*, 108, 1–142. DOI: 10.1007/978-3-030-01099-7_1.
- Miao, Z., Zhao, Y., & Chen, M. (2022). Using flavonoids as a therapeutic intervention against rheumatoid arthritis: The known and unknown. *Pharmacological Research Modern Chinese Medicine*, 3(2022), 100014, 1–9 (9 pages). DOI: 10.1016/j.prmcm.2021.100014.
- Min, H.K., Kim, S.M., Baek, S.Y., Woo, J.W., Park, J.S., Cho, M.L., ... Park, S.H. (2015). Anthocyanin Extracted from Black Soybean Seed Coats Prevents Autoimmune Arthritis by Suppressing the Development of Th17 Cells and Synthesis of Proinflammatory Cytokines by Such Cells via Inhibition of NF- κ B. *PLoS One*, 10(11), e0138201, 1–17 (17 pages). DOI: 10.1371/journal.pone.0138201.
- Mueller, A.L., Payandeh, Z., Mohammadkhani, N., Mubarak, S.M.H., Zakeri, A., Alagheband Bahrami, A., ... Shakibaei, M. (2021). Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. *Cells*, 10(11), 3017, 1–38 (38 pages). DOI: 10.3390/cells10113017.
- Peltzer, K., & Pengpid, S. (2019). The use of herbal medicines among chronic disease patients in Thailand: a cross-sectional survey. *Journal of Multidisciplinary Healthcare*, 12, 573–582. DOI: 10.2147/JMDH.S212953.
- Salehi, B., Sharifi-Rad, J., Cappellini, F., Reiner, Z., Zorzan, D., Imran, M., ... Maroofi, A. (2020). The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. *Frontiers in Pharmacology*, 11, 1300, 1–20 (20 pages). DOI: 10.3389/fphar.2020.01300.
- Sharifi-Rad, J., Quispe, C., Castillo, C.M.S., Caroca, R., Lazo-Vélez, M.A., Antonyak, H., ... Cho, W.C. (2022). Ellagic Acid: A Review on Its Natural Sources, Chemical Stability, and Therapeutic Potential. *Oxidative Medicine and Cellular Longevity*, 2022, 3848084, 1–24 (24 pages). URL: <https://doi.org/10.1155/2022/3848084>.
- Shin, S.A., Joo, B.J., Lee, J.S., Ryu, G., Han, M., Kim, W.Y., ... Lee, C.S. (2020). Phytochemicals as Anti-Inflammatory Agents in Animal Models of Prevalent Inflammatory Diseases. *Molecules*, 25(24), 1–27 (27 pages). DOI: 10.3390/molecules25245932.
- Singh, J.A., Hossain, A., Tanjong Ghogomu, E., Kotb, A., Christensen, R., Mudano, A.S., ... Wells, G.A. (2016). Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews*, 2016(5), CD012183. DOI: 10.1002/14651858.CD012183.
- Singh, S., Singh, T.G., & Mahajan, K. (2020). Medicinal plants used against various inflammatory biomarkers for the management of rheumatoid arthritis. *J. of Pharmacy and Pharmacology*, 72(10), 1306–1327. DOI: 10.1111/jphp.13326.
- Taherian, Maghsoudi, H., & Vaziri, A. (2018). Investigation of Punicic Acid Effects on Matrix Metalloproteinase Genes Expression in Bovine Fibroblast like-Synoviocytes as a Model of Osteoarthritis. *J. of Medicinal Plants*, 17(67), 31–44. URL: <http://jmp.ir/article-1-2262-en.html>.

- Welz, A.N., Emberger-Klein, A., & Menrad, K. (2018). Why people use herbal medicine: insights from a focus-group study in Germany. *BMC Complementary and Alternative Medicine*, 18(1), 1–9 (9 pages). DOI: 10.1186/s12906-018-2160-6.
- Wongrakpanich, S., Wongrakpanich, A., & Melhado, K. (2018). A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. *Aging and Disease*, 9(1), 143–150. DOI: 10.14336/AD.2017.0306.
- Xiong, X., Jiang, X., Lv, G., Yuan, J., Li, M., Lu, Z.K. (2022). Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades. *Frontiers in Pharmacology*, 13, 765226, 1–9 (9 pages). DOI: 10.3389/fphar.2022.765226.
- Xu, J., Cao, K., Liu, X., Zhao, L., Feng, Z., Liu, J. (2021). Punicalagin Regulates Signaling Pathways in Inflammation-Associated Chronic Diseases. *Antioxidants (Basel)*, 11(29), 1–12 (12 pages). DOI: 10.3390/antiox11010029.
- Zhong, Y., Zhang, X., & Chong, W. (2022). Interleukin-24 Immunobiology and Its Roles in Inflammatory Diseases. *International J. of Molecular Sciences*, 23(2), 627, 1–10 (10 pages). DOI: 10.3390/ijms23020627.
- Zuccari, G., Baldassari, S., Ailuno, G., Turrini, F., Alfei, S. & Caviglioli, G. (2020). Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid. *Applied Sciences*, 10(10), 3353, 1–27 (27 pages). DOI: 10.3390/app10103353.

Надійшла до редакції 25.11.2022

Прийнята до друку 20.12.2022

The authors do not have any conflicts of interest to declare.

Contribution of the authors:

Parchami Ghazaei S. – suggesting topic of the article, collecting sources of article, writing the article;

Harnyk T. – reviewing the article, collecting sources of article;

Gorova E. – literature review, conclusions;

Sereda P. – literature review, conclusions;

Marchenko-Tolsta K. – conclusions, proofreading of the text and analysis of literary sources;

Hameed M. – correction and literary editing.

Електронна адреса для листування з авторами: phitotherapy.chasopys@gmail.com



Засновники журналу:

**Таврійський національний університет
імені В.І. Вернадського
Дніпровський медичний інститут традиційної
і нетрадиційної медицини
Всеукраїнська громадська організація
«Асоціація фахівців з народної і нетрадиційної
медицини України»**

Заснований у березні 2002 року. Виходить щоквартально.
Журнал зареєстрований Міністерством юстиції
України 23 грудня 2020 року: Свідоцтво про державну
реєстрацію друкованого засобу масової інформації
Серія КВ № 24626-145661P

УДК 615.322.61.57.014

Мова видання:

статті – українська, англійська; анотації,
ключові слова – українська, англійська.

Передплатний індекс 06684.

Електронна сторінка журналу –
phytotherapy.vernadskyjournals.in.ua

Журнал є фаховим науково-практичним рецензованим
виданням для публікацій основних результатів
дисертаційних робіт у галузі медичних, фармацевтичних,
біологічних наук, у тому числі: медична і фізична
реабілітація, ерготерапія.
Відповідальність за зміст, добір, достовірність наведених
у науково-практичних публікаціях журналу фактів,
статистичних даних, цитат, посилань несуть автори.
Передрук опублікованих статей можливий за згоди
редакції та з посиланням на джерело.

Рекомендовано до друку Вченою Радою Дніпровського
медичного інституту традиційної і нетрадиційної
медицини (Протокол № 7 від 23 лютого 2023 року).

Журнал включено до Переліку наукових фахових видань
України (категорія «Б») з біологічних, медичних
та фармацевтичних наук.

091. *Біологія* відповідно до Наказу МОН України
від 15.04.2021 № 420 (додаток 3), 222. *Медицина*,
226. *Фармація, промислова фармація* відповідно
до Наказу МОН України від 27.09.2021 № 1017 (додаток 3)
та 227. *Фізична терапія, ерготерапія*
відповідно до Наказу МОН України від 06.06.2022 № 530
(додаток 2).

Підписано до друку: 29.05.2023 р.

Формат 60х84/8.

Ум. друк. арк. 15,35.

Зам. № 0723/449

Наклад – 100 прим.

Дизайн та верстка Кузнєцова Н. С.

Видавництво і друкарня – Видавничий дім «Гельветика»

65101, Україна, м. Одеса, вул. Інглезі, 6/1

Телефон +38 (095) 934 48 28, +38 (097) 723 06 08

E-mail: mailbox@helvetica.ua

Свідоцтво суб'єкта видавничої справи

ДК № 7623 від 22.06.2022 р.

Адреса редакції:

04123, Україна, місто Київ, вул. Червоногвардійська, буд. 2В

Телефони: +38 (068) 487 24 43, +38 (050) 353 03 26

Електронна пошта:

editor@phytotherapy.vernadskyjournals.in.ua

phytotherapy.chasopys@gmail.com



Founder:

**V.I. Vernadsky Taurida National University
Dnipropetrovsk Medical Institute of Traditional
and Non-traditional Medicine
NGO "Ukrainian Association for Non-traditional Medicine"**

Established in March, 2002. Published quarterly.
The journal is registered by the Ministry of Justice of Ukraine
as of December 23, 2020. Certificate of state registration
of a print media: Series KB No. 24626-14566IIP

UDC 615.322.61.57.014

Languages:

articles – Ukrainian and English;
abstracts and keywords – Ukrainian and English.

Subscription code: 06684.

Journal's web-page: phytotherapy.vernadskyjournals.in.ua

The journal is a professional peer-reviewed journal that
publishes key findings of thesis research in medicine, pharmacy,
and biology, incl. medical and physical rehabilitation
and ergotherapy.

The authors are responsible for the content, selection and reliability
of facts, statistical data, citations, and references presented in the
journal. The reprinting of published articles is possible upon the
consent of editors and with reference to a source.

Recommended for printing by the Academic Council of
Dnipropetrovsk Medical Institute of Traditional and Non-
traditional Medicine (Minutes No. 7 as of February 23, 2023).

The journal is included in the List of scientific professional
medicine and pharmacy publications of Ukraine ("B" category).

091. *Biology* pursuant to the Order of the MES of Ukraine dated
15.04.2021 No. 420 (annex 3), 222. *Medicine*. 226. *Pharmacy*;
Industrial Pharmacy pursuant to the Order of the MES of Ukraine
dated 27.09.2021 No. 1017 (annex 3), and 227. *Physical Therapy*;
Ergotherapy pursuant to the Order of the MES of Ukraine dated
06.06.2022 No. 530 (annex 2).

Passed for printing: 29.05.2023

Paper size 60x84/8.

Conventional printed sheet. 15,35.

Order No. 0723/449

Print run – 100 copies

Design and layout: Kuznietsova N. S.

Publisher and printing office – Publishing House "Helvetica"

6/1 Inhlezi St, Odesa, 65101

Tel: +38 (095) 934 48 28, +38 (097) 723 06 08

E-mail: mailbox@helvetica.ua

Certificate of a publishing entity
JIK No. 7623 dated 22.06.2022

Editorial office address:

Chervonopolska St., building 2B, Kyiv, Ukraine, 04123

Tel: +38 (068) 487 24 43, +38 (050) 353 03 26

E-mail:

editor@phytotherapy.vernadskyjournals.in.ua

phytotherapy.chasopys@gmail.com